Dynamics of HIV replication in lymphocytes and the efficacy of protease inhibitors

Journal of Medical Virology

Volumn 73, Issue 4, 2004, Pages 502-507

  Bermejo, Mercedes ^a   Sánchez Palomino, Sonsoles ^a   Usán, Luis ^b   Alcamí, José ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b ABBOTT LABORATORIES   (Spain)

Author keywords

Latency; Pharmacodynamics; Protease inhibitors; Reactivation; Viral escape HIV

Indexed keywords

ANTIGEN P24; CELL EXTRACT; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LUCIFERASE; PROTEINASE INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; GENETIC TRANSFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KINETICS; LUCIFERASE REPORTER GENE; LYMPHOCYTE; PERIPHERAL LYMPHOCYTE; PROVIRUS; SUPERNATANT; VIRUS CULTURE; VIRUS ESCAPE; VIRUS EXPRESSION; VIRUS GENE; VIRUS INHIBITION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

DNA, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; RITONAVIR; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; TRANSFECTION; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 3042779447     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20118     Document Type: Article

References (31)

1. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284-291.
2. Alcamí J, Lain de Lera T, Folgueira L, Pedraza MA, Jacque JM, Bachelerie F, Noriega AR, Hay RT, Harrich D, Gaynor RB, et al. 1995. Absolute dependence on kB responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4-lymphocytes. EMBO J 14:1552-1560.
3. Alcamí J, Pedraza MA, Bermejo M, Rullas J. 2000. Kinetics of HIV reactivation from the state of latency. Efficacy of different immune stiluli in triggering HIV replication. XII International AIDS Conference. Durban, South Africa MoOrA172.
4. Blankson N, Persaud D, Siliciano RF. 2002. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 53:557-593.
5. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. 1997. Quantitation of latent tissue reservoirs and total body load in HIV-1 infection. Nature 387:183-188.
6. Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. 2003. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 36:1585-1592.
7. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vezinet F. 2000. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 283:205-211.
8. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP. 1998. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 280:1497-1503.
9. Drusano GL, Bilello JA, Stein DS, Nessly M, Meibohm A, Emini EA, Deutsch P, Condra J, Chodakewitz J, Holder DJ. 1998. Factors influencing the emergence of resistance to indinavir: Role of virologic, immunologic, and pharmacologic variables. J Infect Dis 178:360-367.
10. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
11. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512-517.
12. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM. 1999. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 340:1614-1622.
13. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD. 2000. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 283:229-234.
14. Herz AV, Bonhoeffer S, Anderson RM, May RM, Nowak MA. 1996. Viral dynamics in vivo: Limitations on estimates of intracellular delay and virus decay. Proc Natl Acad Sci USA 93:7247-7251.
15. Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH. 1997. Clinical pharmacology of HIV protease inhibitors: Focus on Saquinavir, Indinavir, and Ritonavir. Pharm World Sci 19:159-175.
16. Kaplan AH, Swanstrom R. 1991. Human immunodeficiency virus type 1 gag proteins are processed in two cellular compartments. Proc Natl Acad Sci USA 88:4528-4532.
17. Kaplan AH, Manchester M, Swanstrom R. 1994. The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J Virol 68:6782-6786.
18. Markowitz M. 2000. Resistance, fitness, adherence, and potency: Mapping the path to virologic failure. JAMA 283:250-251.
19. Mittler JE, Markowitz M, Ho DD, Perelson AS. 1999. Improved estimates of HIV-1 clearance and intracellular delay. AIDS 13:1415-1417.
20. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW, Kempf DJ. 1996. Ordered accumulation of mutations in HIV Protease confers resistance to Ritonavir. Nat Med 2:760-766.
21. Nascimbeni M, Lamotte C, Peytavin G, Farinotti R, Clavel F. 1999. Kinetics of antiviral activity and Intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother 43:2629-2634.
22. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, De Clercq E. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 20:309-321.
23. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in vivo: Virion clearance rate, infected cell lifespan, and viral generation time. Science 271:1582-1586.
24. Persaud D, Zhou Y, Siliciano JM, Siliciano RF. 2003. Latency in HIV-1 infection. No easy answers. J Virol 77:1659-1665.
25. Quillent C, Borman AM, Paulous S, Dauguet C, Clavel F. 1996. Extensive regions of pol are required for efficient HIV polyprotein processing and particle maturation. Virology 219:29-36.
26. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Norbeck DW, et al. 1998. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 42:3218-3224.
27. Van Heeswijk RP, Veldkamp AI, Hoetelmans RM, Mulder JW, Schreij G, Hsu A, Lange JM, Beijnen JH, Meenhorst PL. 1999. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 13:F95-F99.
28. Witvrouw W, Pannecouque C, Fikkert V, Hantson A, Van Remoortel B, Hezareh M, DeClerq E, Brown SJ. 2003. Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry. Antivir Chem Chemother 14:321-328.
29. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
30. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. 1990. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 61:213-222.
31. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD. 1999. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 340:1605-1613.